Table of Contents Author Guidelines Submit a Manuscript
Letter to the Editor
BioMed Research International
Volume 2018, Article ID 3293584, 9 pages
https://doi.org/10.1155/2018/3293584
Research Article

Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding

1Universities of Giessen and Marburg Lung Centre (UGMLC), Aulweg 130, 35392 Giessen, Germany
2German Center for Lung Research (DZL), 35392 Giessen, Germany
3Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany
4Bayer Pharma AG, Aprather Weg 18a, 42096 Wuppertal, Germany
5Institute of Pharmacy, Martin Luther University of Halle-Wittenberg, Wolfgang-Langenbeck-Strasse 4, 06120 Halle (Saale), Germany

Correspondence should be addressed to Ralph Theo Schermuly; ed.nesseig-inu.dem.erenni@ylumrehcs.hplar

Received 7 July 2017; Revised 4 November 2017; Accepted 16 November 2017; Published 3 January 2018

Academic Editor: Ruxandra Jurcut

Copyright © 2018 Nabham Rai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Grignola, “Hemodynamic assessment of pulmonary hypertension,” World Journal of Cardiology, vol. 3, no. 1, p. 10, 2011. View at Publisher · View at Google Scholar
  2. J. A. Leopold and B. A. Maron, “Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension,” International Journal of Molecular Sciences, vol. 17, no. 5, article no. 761, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Ryan and S. L. Archer, “The right ventricle in pulmonary arterial hypertension: Disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure,” Circulation Research, vol. 115, no. 1, pp. 176–188, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. K. M. Chin, N. H. S. Kim, and L. J. Rubin, “The right ventricle in pulmonary hypertension,” Coronary Artery Disease, vol. 16, no. 1, pp. 13–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. V. V. McLaughlin, “Looking to the future: A new decade of pulmonary arterial hypertension therapy,” European Respiratory Review, vol. 20, no. 122, pp. 262–269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. C. Price, S. J. Wort, S. J. Finney, P. S. Marino, and S. J. Brett, “Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review,” Critical Care, vol. 14, no. 5, article R169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Koress, K. Swan, and P. Kadowitz, “Soluble guanylate cyclase stimulators and activators: novel therapies for pulmonary vascular disease or a different method of increasing cGMP?” Current Hypertension Reports, vol. 18, no. 5, article no. 42, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. J. O. Lundberg, M. T. Gladwin, and E. Weitzberg, “Strategies to increase nitric oxide signalling in cardiovascular disease,” Nature Reviews Drug Discovery, vol. 14, no. 9, pp. 623–641, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Ghofrani, M. Humbert, D. Langleben et al., “Riociguat: mode of action and clinical development in pulmonary hypertension,” Chest, vol. 151, no. 2, pp. 468–480, 2017. View at Publisher · View at Google Scholar
  10. P. Sandner and J. P. Stasch, “Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence,” Respiratory Medicine, vol. 122, pp. S1–S9, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Gheorghiade, C. N. Marti, H. N. Sabbah et al., “Soluble guanylate cyclase: A potential therapeutic target for heart failure,” Heart Failure Reviews, vol. 18, no. 2, pp. 123–134, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. T. A. McKinsey and D. A. Kass, “Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface,” Nature Reviews Drug Discovery, vol. 6, no. 8, pp. 617–635, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Kraehling and W. C. Sessa, “Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease,” Circulation Research, vol. 120, no. 7, pp. 1174–1182, 2017. View at Publisher · View at Google Scholar · View at Scopus
  14. H. A. Ghofrani, N. Galiè, F. Grimminger et al., “Riociguat for the treatment of pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 369, no. 4, pp. 330–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Wardle, R. Wardle, K. Luyt, and R. Tulloh, “The utility of sildenafil in pulmonary hypertension: A focus on bronchopulmonary dysplasia,” Archives of Disease in Childhood, vol. 98, no. 8, pp. 613–617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Galiè, H. A. Ghofrani, A. Torbicki et al., “Sildenafil citrate therapy for pulmonary arterial hypertension,” The New England Journal of Medicine, vol. 353, no. 20, pp. 2148–2157, 2005. View at Google Scholar
  17. M. A. J. Borgdorff, B. Bartelds, M. G. Dickinson et al., “Sildenafil enhances systolic adaptation, but does not prevent diastolic dysfunction, in the pressure-loaded right ventricle,” European Journal of Heart Failure, vol. 14, no. 9, pp. 1067–1074, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. M. S. Fernandes, A. C. Andrade, N. D. Barroso et al., “The immediate effect of Sildenafil on right ventricular function in patients with heart failure measured by cardiac magnetic resonance: A randomized control trial,” PLoS ONE, vol. 10, no. 3, Article ID e0119623, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Guazzi, G. Tumminello, F. Di Marco, C. Fiorentini, and M. D. Guazzi, “The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure,” Journal of the American College of Cardiology, vol. 44, no. 12, pp. 2339–2348, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. H. K. Bae, H. Lee, K. C. Kim, and Y. M. Hong, “The effect of sildenafil on right ventricular remodeling in a rat model of monocrotaline-induced right ventricular failure,” Korean Journal of Pediatrics, vol. 59, no. 6, pp. 262–270, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Yoshiyuki, R. Tanaka, R. Fukushima, and N. Machida, “Preventive effect of sildenafil on right ventricular function in rats with monocrotaline-induced pulmonary arterial hypertension,” Journal of Experimental Animal Science, vol. 65, no. 3, pp. 215–222, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Schafer, P. Ellinghaus, W. Janssen et al., “Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling,” Cardiovascular Research, vol. 82, no. 1, pp. 30–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Lang, B. Kojonazarov, X. Tian et al., “The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats,” PLoS ONE, vol. 7, no. 8, Article ID e43433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. M. A. Borgdorff, B. Bartelds, M. G. Dickinson et al., “Sildenafil treatment in established right ventricular dysfunction improves diastolic function and attenuates interstitial fibrosis independent from afterload,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 307, no. 3, pp. H361–H369, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. R. T. Schermuly, J.-P. Stasch, S. S. Pullamsetti et al., “Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension,” European Respiratory Journal, vol. 32, no. 4, pp. 881–891, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Novoyatleva, Y. Schymura, W. Janssen et al., “Deletion of Fn14 receptor protects from right heart fibrosis and dysfunction,” Basic Research in Cardiology, vol. 108, no. 2, article 325, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J.-P. Stasch and O. V. Evgenov, “Soluble guanylate cyclase stimulators in pulmonary hypertension,” Handbook of Experimental Pharmacology, vol. 218, pp. 279–313, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. J.-P. Stasch, P. Pacher, and O. V. Evgenov, “Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease,” Circulation, vol. 123, no. 20, pp. 2263–2273, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Pradhan, A. Sydykov, X. Tian et al., “Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice,” International Journal of Cardiology, vol. 216, pp. 85–91, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Dumitrascu, N. Weissmann, H. A. Ghofrani et al., “Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling,” Circulation, vol. 113, no. 2, pp. 286–295, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. B. Egemnazarov, A. Schmidt, S. Crnkovic et al., “Pressure overload creates right ventricular diastolic dysfunction in a mouse model: assessment by echocardiography,” Journal of the American Society of Echocardiography, vol. 28, no. 7, pp. 828–843, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. L. B. Thorsen, Y. Eskildsen-Helmond, H. Zibrandtsen, J.-P. Stasch, U. Simonsen, and B. E. Laursen, “BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats,” European Journal of Pharmacology, vol. 647, no. 1-3, pp. 147–154, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Breitenstein, L. Roessig, P. Sandner, and K. S. Lewis, “Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure,” in Journal of Cardiac Failure, vol. 243 of Handbook of Experimental Pharmacology, pp. 225–247, Springer International Publishing, Cham, 2017. View at Publisher · View at Google Scholar
  34. D. Conole and L. J. Scott, “Riociguat: First global approval,” Drugs, vol. 73, no. 17, pp. 1967–1975, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Sharkovska, P. Kalk, B. Lawrenz et al., “Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models,” Journal of Hypertension, vol. 28, no. 8, pp. 1666–1675, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. G. Maarman, S. Lecour, G. Butrous, F. Thienemann, and K. Sliwa, “A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet?” Pulmonary Circulation, vol. 3, no. 4, pp. 739–756, 2013. View at Publisher · View at Google Scholar
  37. E. Schinner, V. Wetzl, A. Schramm et al., “Inhibition of the TGFβ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis,” FEBS Open Bio, vol. 7, no. 4, pp. 550–561, 2017. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Masuyama, T. Tsuruda, Y. Sekita et al., “Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart,” Hypertension Research, vol. 32, no. 7, pp. 597–603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Dobaczewski, W. Chen, and N. G. Frangogiannis, “Transforming growth factor (TGF)-β signaling in cardiac remodeling,” Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 600–606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. W. Song and X. Wang, “The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure,” Biophysical Reviews, vol. 7, no. 1, pp. 91–104, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Bonniaud, P. J. Margetts, K. Ask, K. Flanders, J. Gauldie, and M. Kolb, “TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis,” The Journal of Immunology, vol. 175, no. 8, pp. 5390–5395, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Euler-Taimor and J. Heger, “The complex pattern of SMAD signaling in the cardiovascular system,” Cardiovascular Research, vol. 69, no. 1, pp. 15–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Ruiz-Ortega, J. Rodríguez-Vita, E. Sanchez-Lopez, G. Carvajal, and J. Egido, “TGF-β signaling in vascular fibrosis,” Cardiovascular Research, vol. 74, no. 2, pp. 196–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. W. Gong, M. Yan, J. Chen, S. Chaugai, C. Chen, and D. Wang, “Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor β-induced Smad signaling,” Frontiers of Medicine, vol. 8, no. 4, pp. 445–455, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. C. Methner, G. Buonincontri, C.-I. Hu et al., “Riociguat reduces infarct size and post-infarct heart failure in mouse hearts: Insights from MRI/PET imaging,” PLoS ONE, vol. 8, no. 12, Article ID e83910, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Geschka, A. Kretschmer, Y. Sharkovska et al., “Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive dahl rats,” PLoS ONE, vol. 6, no. 7, Article ID e21853, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Rain, S. Andersen, A. Najafi et al., “Right ventricular myocardial stiffness in experimental pulmonary arterial hypertensionclinical perspective,” Circulation: Heart Failure, vol. 9, no. 7, p. e002636, 2016. View at Publisher · View at Google Scholar